531 656
[47]
Droz JP, Efstathiou E, Yildirim A, et al. First-line treatment in senior adults with metastatic castration-resistant prostate cancer: a pro- spective international registry. Urol Oncol 2016;34:234–9.[48]
Heidenreich A, Bracarda S, Mason M, et al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Eur J Can- cer 2014;50:1090–9.[49]
de Bono JS, Hardy-Bessard AC, Choung-Soo K. Phase III non-inferi- ority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D). J Clin Oncol 2016;34(Suppl):5008.[50]
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus predni- sone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA- 302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152–60.[51]
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzaluta- mide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187–97.[52]
Sternberg CN, de Bono JS, Chi KN, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate can- cer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol 2014;25:429–34.
[53]
Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in meta- static prostate cancer before chemotherapy. N Engl J Med 2014;371:424–33.[54]
Graff JN, Baciarello G, Armstrong AJ, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy- naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol 2016;27:286–94.
[55]
Maines F, Caffo O, Veccia A, et al. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol 2015;96:498–506.[56]
Moss AH, Lunney JR, Culp S, et al. Prognostic significance of the ‘‘surprise’’ question in cancer patients. J Palliat Med 2010;13: 837–40.[57]
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733–42.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 5 2 1 – 5 3 1
531